Eloxx Pharmaceuticals Inc
ELOX
Get informed when a big investor buys or sells
+ FollowMarket Cap$60.38M
Close$
$3.38
82.3% downside
Current Fair Value
82.3% downsideOvervalued by 82.3% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $60.38 Million |
|---|---|
| Enterprise Value | $54.01 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-5.39 |
| Beta | -9.95 |
| Outstanding Shares | 4,382,295 |
Return
| Return on Equity | 236.25% |
|---|---|
| Return on Assets | -210.71% |
| Return on Invested Capital | 224.78% |
Valuation & Multiples
| P/E Ratio | -3.01 |
|---|---|
| PEG | -66.82 |
| Price to Sales | - |
| Price to Book Ratio | 19.07 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -3.17 |
| Enterprise Value to Net Income | -4 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 11, 2026
EPS Estimate
$-70.40
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
November 11, 2026
EPS Estimate
$-55.73
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Eloxx Pharmaceuticals Inc
CEO: Robert Ward